Pharma and Biotech Firms Hacked

Cyberspies have broken into the e-mails of a number of publicly traded companies, most of which are in health care and pharmaceuticals.

Written byKerry Grens
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, CHIEF PHOTOGRAPHER/MODA group of cyber attackers, dubbed FIN4, has hacked into the e-mail networks of more than 100 companies in the last year and a half, according to a new report from the security firm FireEye. The majority of the targets are executives, scientists, legal counsel, and others with sensitive information at health-care and pharmaceutical companies.

“FireEye believes FIN4 intentionally targets individuals who have inside information about impending market catalysts—events that will cause the price of stocks to rise or fall substantially in a short period of time,” the firm wrote in its report.

The attackers use clever decoys to lure their victims into clicking on link, which then asks for login information that FIN4 then steals to read their e-mails. The New York Times reported, for instance, that “[s]ome senior executives have been duped into clicking on links sent from the accounts of longtime clients, in which the supposed client reveals that they found an employee’s negative comments about the executive in an investment forum. In other cases, attackers have used confidential company documents, which they had previously stolen, as ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies